
David Robert Vincent
Examiner (ID: 210, Phone: (571)272-3080 , Office: P/2124 )
| Most Active Art Unit | 2123 |
| Art Unit(s) | 2615, 2713, 2129, 3628, 2124, 2787, 2732, 2731, 2661, 2123 |
| Total Applications | 1769 |
| Issued Applications | 1423 |
| Pending Applications | 132 |
| Abandoned Applications | 223 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17460276
[patent_doc_number] => 20220073581
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-10
[patent_title] => ANTIBODIES COMPRISING A POLYPEPTIDE INSERTED IN FRAMEWORK 3 REGION
[patent_app_type] => utility
[patent_app_number] => 17/259090
[patent_app_country] => US
[patent_app_date] => 2019-07-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20680
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -42
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17259090
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/259090 | Antibodies comprising a polypeptide inserted in framework 3 region | Jul 9, 2019 | Issued |
Array
(
[id] => 17082112
[patent_doc_number] => 20210277118
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-09
[patent_title] => COMPOSITIONS INCLUDING CD3 ANTIGEN BINDING FRAGMENTS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/254105
[patent_app_country] => US
[patent_app_date] => 2019-06-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 41212
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17254105
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/254105 | Compositions including CD3 antigen binding fragments and uses thereof | Jun 19, 2019 | Issued |
Array
(
[id] => 15454549
[patent_doc_number] => 20200040099
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-02-06
[patent_title] => Single chain binding molecules comprising N-terminal ABP
[patent_app_type] => utility
[patent_app_number] => 16/444144
[patent_app_country] => US
[patent_app_date] => 2019-06-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30054
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16444144
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/444144 | Single chain binding molecules comprising N-terminal ABP | Jun 17, 2019 | Abandoned |
Array
(
[id] => 15267533
[patent_doc_number] => 20190382500
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-19
[patent_title] => BCMA CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/439495
[patent_app_country] => US
[patent_app_date] => 2019-06-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 85158
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16439495
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/439495 | BCMA chimeric antigen receptors and uses thereof | Jun 11, 2019 | Issued |
Array
(
[id] => 17214505
[patent_doc_number] => 20210347842
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-11
[patent_title] => COMPOSITIONS AND METHODS OF USE OF IL-10 AGENTS IN CONJUNCTION WITH CHIMERIC ANTIGEN RECEPTOR CELL THERAPY
[patent_app_type] => utility
[patent_app_number] => 15/733970
[patent_app_country] => US
[patent_app_date] => 2019-06-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 51687
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15733970
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/733970 | COMPOSITIONS AND METHODS OF USE OF IL-10 AGENTS IN CONJUNCTION WITH CHIMERIC ANTIGEN RECEPTOR CELL THERAPY | Jun 11, 2019 | Abandoned |
Array
(
[id] => 16948136
[patent_doc_number] => 20210206827
[patent_country] => US
[patent_kind] => A9
[patent_issue_date] => 2021-07-08
[patent_title] => COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS
[patent_app_type] => utility
[patent_app_number] => 16/436110
[patent_app_country] => US
[patent_app_date] => 2019-06-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 47487
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16436110
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/436110 | COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS | Jun 9, 2019 | Abandoned |
Array
(
[id] => 16948136
[patent_doc_number] => 20210206827
[patent_country] => US
[patent_kind] => A9
[patent_issue_date] => 2021-07-08
[patent_title] => COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS
[patent_app_type] => utility
[patent_app_number] => 16/436110
[patent_app_country] => US
[patent_app_date] => 2019-06-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 47487
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16436110
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/436110 | COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS | Jun 9, 2019 | Abandoned |
Array
(
[id] => 15144997
[patent_doc_number] => 20190350976
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-21
[patent_title] => Methods for handling biological drugs containing living cells
[patent_app_type] => utility
[patent_app_number] => 16/433659
[patent_app_country] => US
[patent_app_date] => 2019-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8645
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 84
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16433659
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/433659 | Methods for handling biological drugs containing living cells | Jun 5, 2019 | Issued |
Array
(
[id] => 15267509
[patent_doc_number] => 20190382488
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-19
[patent_title] => ANTIGEN BINDING CONSTRUCTS TO CD8
[patent_app_type] => utility
[patent_app_number] => 16/417482
[patent_app_country] => US
[patent_app_date] => 2019-05-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25974
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16417482
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/417482 | ANTIGEN BINDING CONSTRUCTS TO CD8 | May 19, 2019 | Abandoned |
Array
(
[id] => 15267507
[patent_doc_number] => 20190382487
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-19
[patent_title] => ANTIGEN BINDING CONSTRUCTS TO CD8
[patent_app_type] => utility
[patent_app_number] => 16/417474
[patent_app_country] => US
[patent_app_date] => 2019-05-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22505
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16417474
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/417474 | ANTIGEN BINDING CONSTRUCTS TO CD8 | May 19, 2019 | Abandoned |
Array
(
[id] => 15038593
[patent_doc_number] => 20190330301
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-31
[patent_title] => T CELL RECEPTORS
[patent_app_type] => utility
[patent_app_number] => 16/416907
[patent_app_country] => US
[patent_app_date] => 2019-05-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11066
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 121
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16416907
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/416907 | T cell receptors | May 19, 2019 | Issued |
Array
(
[id] => 15664069
[patent_doc_number] => 10596242
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-03-24
[patent_title] => Transfected T-cells and T-cell receptors for use in immunotherapy against cancers
[patent_app_type] => utility
[patent_app_number] => 16/413939
[patent_app_country] => US
[patent_app_date] => 2019-05-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 18647
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 156
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16413939
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/413939 | Transfected T-cells and T-cell receptors for use in immunotherapy against cancers | May 15, 2019 | Issued |
Array
(
[id] => 14778021
[patent_doc_number] => 20190263908
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-08-29
[patent_title] => Immunoglobulins binding human Vγ9Vδ2 T cell receptors
[patent_app_type] => utility
[patent_app_number] => 16/414424
[patent_app_country] => US
[patent_app_date] => 2019-05-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11452
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16414424
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/414424 | Immunoglobulins binding human Vγ9Vδ2 T cell receptors | May 15, 2019 | Abandoned |
Array
(
[id] => 14746833
[patent_doc_number] => 20190256590
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-08-22
[patent_title] => NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 16/403269
[patent_app_country] => US
[patent_app_date] => 2019-05-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22772
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 458
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16403269
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/403269 | T cell receptors and immune therapy using the same | May 2, 2019 | Issued |
Array
(
[id] => 15784907
[patent_doc_number] => 10626160
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-04-21
[patent_title] => Transfected T-cells and T-cell receptors for use in immunotherapy against cancers
[patent_app_type] => utility
[patent_app_number] => 16/403058
[patent_app_country] => US
[patent_app_date] => 2019-05-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 17
[patent_no_of_words] => 33330
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 127
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16403058
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/403058 | Transfected T-cells and T-cell receptors for use in immunotherapy against cancers | May 2, 2019 | Issued |
Array
(
[id] => 16369104
[patent_doc_number] => 10800845
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-10-13
[patent_title] => T cell receptors and immune therapy using the same
[patent_app_type] => utility
[patent_app_number] => 16/402829
[patent_app_country] => US
[patent_app_date] => 2019-05-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 12
[patent_no_of_words] => 12319
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 142
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16402829
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/402829 | T cell receptors and immune therapy using the same | May 2, 2019 | Issued |
Array
(
[id] => 16549760
[patent_doc_number] => 10882909
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-01-05
[patent_title] => Antigen binding constructs to CD3
[patent_app_type] => utility
[patent_app_number] => 16/394957
[patent_app_country] => US
[patent_app_date] => 2019-04-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 58
[patent_figures_cnt] => 68
[patent_no_of_words] => 22448
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 78
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16394957
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/394957 | Antigen binding constructs to CD3 | Apr 24, 2019 | Issued |
Array
(
[id] => 17007094
[patent_doc_number] => 20210238255
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-05
[patent_title] => CHIMERIC HLA ACCESSORY RECEPTOR
[patent_app_type] => utility
[patent_app_number] => 17/050289
[patent_app_country] => US
[patent_app_date] => 2019-04-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24063
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -38
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17050289
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/050289 | CHIMERIC HLA ACCESSORY RECEPTOR | Apr 17, 2019 | Abandoned |
Array
(
[id] => 17274506
[patent_doc_number] => 20210380704
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-09
[patent_title] => CHIMERIC ANTIGEN RECEPTOR SPECIFIC FOR INTERLEUKIN-23 RECEPTOR
[patent_app_type] => utility
[patent_app_number] => 17/047232
[patent_app_country] => US
[patent_app_date] => 2019-04-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 45525
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17047232
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/047232 | Chimeric antigen receptor specific for interleukin-23 receptor | Apr 14, 2019 | Issued |
Array
(
[id] => 14881651
[patent_doc_number] => 10420846
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-09-24
[patent_title] => Bifunctional polypeptides
[patent_app_type] => utility
[patent_app_number] => 16/378505
[patent_app_country] => US
[patent_app_date] => 2019-04-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 17
[patent_no_of_words] => 8873
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 67
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16378505
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/378505 | Bifunctional polypeptides | Apr 7, 2019 | Issued |